Scholarlink

<p>Radiohalogens, including fluorine-18 (F-18) and radioiodine (I-123, I-124, and I-131), have been utilized widely for both diagnostic imaging and targeted radionuclide therapy owing to their favorable nuclear properties, well-established radiochemistry, and broad applicability to biomolecules. Among the diverse radionuclides utilized in this field, the production of astatine-211, a promising alpha-emitting radiohalogen, has expanded globally, stimulating a growing interest in theranostic applications that leverage the unique properties of radiohalogens. This review article provides an overview of radiohalogens in nuclear medicine, discussing their current status and future prospects in theranostic radiopharmaceuticals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Theranostic Application of Radiohalogens in Nuclear Medicine

  • 期刊论文

  • 发表日期：

    2025年8月16日

查看全文
  • Choong Mo Kang

摘要

Radiohalogens, including fluorine-18 (F-18) and radioiodine (I-123, I-124, and I-131), have been utilized widely for both diagnostic imaging and targeted radionuclide therapy owing to their favorable nuclear properties, well-established radiochemistry, and broad applicability to biomolecules. Among the diverse radionuclides utilized in this field, the production of astatine-211, a promising alpha-emitting radiohalogen, has expanded globally, stimulating a growing interest in theranostic applications that leverage the unique properties of radiohalogens. This review article provides an overview of radiohalogens in nuclear medicine, discussing their current status and future prospects in theranostic radiopharmaceuticals.